HIV care in Central and Eastern Europe: How close are we to the target?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376809" target="_blank" >RIV/00216208:11110/18:10376809 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/18:10376809 RIV/00064211:_____/18:W0000114
Result on the web
<a href="https://doi.org/10.1016/j.ijid.2018.03.007" target="_blank" >https://doi.org/10.1016/j.ijid.2018.03.007</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijid.2018.03.007" target="_blank" >10.1016/j.ijid.2018.03.007</a>
Alternative languages
Result language
angličtina
Original language name
HIV care in Central and Eastern Europe: How close are we to the target?
Original language description
Objectives: The aim of this survey was to describe the current status of HIV care in the countries of Central and Eastern Europe and to investigate how close the region is to achieving the UNAIDS 2020 target of 9090-90. Methods: In 2014, data were collected from 24 Central and Eastern European countries using a 38-item questionnaire. Results: All countries reported mandatory screening of blood and organ donors for HIV. Other groups subjected to targeted screening included people who inject drugs (PWID) (15/24, 62.5%), men who have sex with men (MSM) (14/24, 58.3%), and sex workers (12/24, 50.0%). Only 14 of the 24 countries (58.3%) screened pregnant women. The percentages of late presentation and advanced disease were 40.3% (range 14-80%) and 25.4% (range 9-50%), respectively. There was no difference between countries categorized by income or by region in terms of the percentages of persons presenting late or with advanced disease. The availability of newer antiretroviral drugs (rilpivirine, etravirine, darunavir, maraviroc, raltegravir, dolutegravir) tended to be significantly better with a higher country income status. Ten countries reported initiating antiretroviral therapy (ART) regardless of CD4+ T cell count (41.7%), five countries (20.8%) used the threshold of <500 cells/mu l, and nine countries (37.5%) used the threshold of <350cells/ mu I. Initiation of ART regardless of the CD4+ T cell count was significantly more common among highincome countries than among upper-middle-income and lower-middle-income countries (100% vs. 27.3% and 0%, respectively; p = 0.001). Drugs were provided free of charge in all countries and mostly provided by governments. There were significant discrepancies between countries regarding the follow-up of people living with HIV. Conclusions: There are major disparities in the provision of HIV care among sub-regions in Europe, which should be addressed. More attention in terms of funding, knowledge and experience sharing, and capacity building is required for the resource-limited settings of Central and Eastern Europe. The exact needs should be defined and services scaled up in order to achieve a standard level of care and provide an adequate and sustainable response to the HIV epidemic in this region.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Infectious Diseases
ISSN
1201-9712
e-ISSN
—
Volume of the periodical
70
Issue of the periodical within the volume
May
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
121-130
UT code for WoS article
000432658100022
EID of the result in the Scopus database
2-s2.0-85045436903